CL2016002072A1 - 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer - Google Patents
2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimerInfo
- Publication number
- CL2016002072A1 CL2016002072A1 CL2016002072A CL2016002072A CL2016002072A1 CL 2016002072 A1 CL2016002072 A1 CL 2016002072A1 CL 2016002072 A CL2016002072 A CL 2016002072A CL 2016002072 A CL2016002072 A CL 2016002072A CL 2016002072 A1 CL2016002072 A1 CL 2016002072A1
- Authority
- CL
- Chile
- Prior art keywords
- trifluoro
- alzheimer
- disease
- amino
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D227/00—Heterocyclic compounds containing rings having one nitrogen atom as the only ring hetero atom, according to more than one of groups C07D203/00 - C07D225/00
- C07D227/02—Heterocyclic compounds containing rings having one nitrogen atom as the only ring hetero atom, according to more than one of groups C07D203/00 - C07D225/00 with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D227/06—Heterocyclic compounds containing rings having one nitrogen atom as the only ring hetero atom, according to more than one of groups C07D203/00 - C07D225/00 with only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D227/10—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA201400086 | 2014-02-19 | ||
| DKPA201400349 | 2014-07-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2016002072A1 true CL2016002072A1 (es) | 2017-01-20 |
Family
ID=59009438
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2016002072A CL2016002072A1 (es) | 2014-02-19 | 2016-08-17 | 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US20170066741A1 (esLanguage) |
| EP (1) | EP3107897A1 (esLanguage) |
| JP (1) | JP6483146B2 (esLanguage) |
| KR (1) | KR20160115936A (esLanguage) |
| CN (1) | CN106029639B (esLanguage) |
| AP (1) | AP2016009370A0 (esLanguage) |
| AR (1) | AR099489A1 (esLanguage) |
| AU (1) | AU2015220873A1 (esLanguage) |
| CA (1) | CA2940028A1 (esLanguage) |
| CL (1) | CL2016002072A1 (esLanguage) |
| CR (1) | CR20160352A (esLanguage) |
| DO (1) | DOP2016000194A (esLanguage) |
| EA (1) | EA031132B1 (esLanguage) |
| EC (1) | ECSP16072941A (esLanguage) |
| GE (2) | GEAP201814248A (esLanguage) |
| IL (1) | IL246875A0 (esLanguage) |
| MA (1) | MA39225A1 (esLanguage) |
| MX (1) | MX2016010777A (esLanguage) |
| PE (1) | PE20161225A1 (esLanguage) |
| PH (1) | PH12016501600A1 (esLanguage) |
| RU (1) | RU2016133626A (esLanguage) |
| SG (1) | SG11201606812WA (esLanguage) |
| TW (1) | TW201609700A (esLanguage) |
| UA (1) | UA117695C2 (esLanguage) |
| WO (1) | WO2015124576A1 (esLanguage) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GEAP201814248A (en) | 2014-02-19 | 2018-04-10 | H Lundbeck As | 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease |
| JO3458B1 (ar) | 2014-11-10 | 2020-07-05 | H Lundbeck As | 2- أمينو-6- (دايفلوروميثيل) – 5، 5- ديفلورو-6-فينيل-3،4، 5، 6-تيتراهيدروبيريدين كمثبطات bace1 |
| CR20170187A (es) | 2014-11-10 | 2018-02-01 | H Lundbeck As | 2-Amino-3,5-difluoro-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas en calidad de inhibidores de BACE1 para el tratamiento de la enfermedad de Alzheimer |
| MA40941A (fr) * | 2014-11-10 | 2017-09-19 | H Lundbeck As | 2-amino-5,5-difluoro-6-(fluorométhyl)-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1 |
| JO3627B1 (ar) | 2015-04-30 | 2020-08-27 | H Lundbeck As | إيميدازو بيرازينونات على هيئة مثبطات pde1 |
| TW201717948A (zh) | 2015-08-10 | 2017-06-01 | Ｈ 朗德貝克公司 | 包括給予２－胺基－３，５，５－三氟－３，４，５，６－四氫吡啶的聯合治療 |
| BR112017007472A2 (pt) * | 2015-08-12 | 2018-01-23 | H Lundbeck As | 2-amino-3-fluoro-3-(fluoro metil)-6-metil-6-fenil- 3,4,5,6-tetra-hidropiridinas como inibidores de bace1 |
| EP3702470A3 (en) * | 2015-09-09 | 2020-10-07 | The Trustees of Columbia University in the City of New York | Reduction of er-mam-localized app-c99 and methods of treating alzheimer's disease |
| TW201726651A (zh) * | 2015-09-23 | 2017-08-01 | 健生藥品公司 | ２，３，４，５－四氫吡啶－６－胺衍生物 |
| US10034861B2 (en) | 2016-07-04 | 2018-07-31 | H. Lundbeck A/S | 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors |
| PL3532064T3 (pl) | 2016-10-28 | 2020-11-16 | H. Lundbeck A/S | Terapie skojarzone obejmujące imidazopirazynony do leczenia zaburzeń psychiatrycznych i/lub poznawczych |
| MA46621A (fr) | 2016-10-28 | 2021-06-02 | H Lundbeck As | Traitements combinés comprenant l'administration d'imidazopyrazinones |
| TW201829394A (zh) | 2016-12-21 | 2018-08-16 | 丹麥商Ｈ 朗德貝克公司 | 作為ｂａｃｅ１抑制劑之６-胺基-５-氟-５-（氟甲基）-２，３，４，５-四氫吡啶-２-基-苯基-５-（甲氧基-ｄ）-吡-２-甲醯胺及其氟化衍生物 |
| US10342786B2 (en) | 2017-10-05 | 2019-07-09 | Fulcrum Therapeutics, Inc. | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD |
| JP7012152B2 (ja) | 2017-10-05 | 2022-02-10 | フルクラム セラピューティクス，インコーポレイテッド | Ｆｓｈｄの治療のためにｄｕｘ４および下流遺伝子発現を低減するｐ３８キナーゼ阻害剤 |
| AR113926A1 (es) | 2017-12-14 | 2020-07-01 | H Lundbeck As | Derivados de 1h-pirazolo[4,3-b]piridinas |
| PL3723807T3 (pl) | 2017-12-14 | 2022-01-24 | H. Lundbeck A/S | Leczenie skojarzone obejmujące podawanie 1h-pirazolo[4,3-b]pirydyn |
| WO2019121840A1 (en) | 2017-12-20 | 2019-06-27 | H. Lundbeck A/S | Pyrazolo[3,4-b]pyridines and imidazo[1,5-b]pyridazines as pde1 inhibitors |
| KR102507861B1 (ko) | 2018-04-19 | 2023-03-09 | 삼성에스디에스 주식회사 | 부채널 공격에 안전한 연산 장치 및 방법 |
| KR102510077B1 (ko) | 2018-04-24 | 2023-03-14 | 삼성에스디에스 주식회사 | 부채널 공격에 안전한 연산 장치 및 방법 |
| US12042492B2 (en) | 2020-10-09 | 2024-07-23 | Texas Tech University System | BACE1 inhibitory ligand molecules against amyloid beta-induced synaptic and mitochondrial toxicities |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005505506A (ja) * | 2001-06-12 | 2005-02-24 | イーラン ファーマスーティカルズ、インコーポレイテッド | アルツハイマー病の治療に有用な大環状分子 |
| GB0124928D0 (en) * | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
| SI1474395T1 (sl) * | 2002-02-12 | 2008-02-29 | Smithkline Beecham Corp | Nikotinamidni derivati, uporabni kot inhibitorji p38 |
| TWI431004B (zh) * | 2008-05-02 | 2014-03-21 | Lilly Co Eli | Ｂａｃｅ抑制劑 |
| WO2011154431A1 (en) * | 2010-06-09 | 2011-12-15 | Janssen Pharmaceutica Nv | 5,6-dihydro-2h-[1,4]oxazin-3-yl-amine derivatives useful as inhibitors of beta-secretase (bace) |
| CN103261199A (zh) * | 2010-10-29 | 2013-08-21 | 盐野义制药株式会社 | 萘啶衍生物 |
| AU2012206555A1 (en) | 2011-01-12 | 2013-08-01 | Novartis Ag | Oxazine derivatives and their use in the treatment of neurological disorders |
| US8637508B2 (en) * | 2011-01-13 | 2014-01-28 | Novartis Ag | Heterocyclic derivatives and their use in the treatment of neurological disorders |
| US8754075B2 (en) * | 2011-04-11 | 2014-06-17 | Hoffmann-La Roche Inc. | 1,3-oxazines as BACE1 and/or BACE2 inhibitors |
| TW201247635A (en) * | 2011-04-26 | 2012-12-01 | Shionogi & Co | Oxazine derivatives and a pharmaceutical composition for inhibiting BAC1 containing them |
| CN103717592A (zh) * | 2011-06-07 | 2014-04-09 | 霍夫曼-拉罗奇有限公司 | 作为bace1和/或bace2抑制剂的卤代-烷基-1,3噁嗪类 |
| UY34278A (es) * | 2011-08-25 | 2013-04-05 | Novartis Ag | Derivados novedosos de oxazina y su uso en el tratamiento de enfermedades |
| US8338413B1 (en) * | 2012-03-07 | 2012-12-25 | Novartis Ag | Oxazine derivatives and their use in the treatment of neurological disorders |
| BR112014023384A8 (pt) | 2012-03-20 | 2018-01-16 | R Artis Dean | inibidores de bace espirocíclicos de di-hidro-tiazina e di-hidro-oxazina, e composições e usos dos mesmos. |
| WO2014056816A1 (en) | 2012-10-10 | 2014-04-17 | F. Hoffmann-La Roche Ag | COMBINATION OF AN Aβ ANTIBODY AND A BACE INHIBITOR |
| EP2912035A4 (en) | 2012-10-24 | 2016-06-15 | Shionogi & Co | DERIVATIVES OF DIHYDROOXAZINE OR OXAZEPINE HAVING BACE1 INHIBITING ACTIVITY |
| US9296734B2 (en) | 2013-03-01 | 2016-03-29 | Amgen Inc. | Perfluorinated 5,6-dihydro-4H-1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of use |
| GEAP201814248A (en) | 2014-02-19 | 2018-04-10 | H Lundbeck As | 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease |
| TW201623295A (zh) | 2014-04-11 | 2016-07-01 | 塩野義製藥股份有限公司 | 具有ｂａｃｅ１抑制活性之二氫噻及二氫衍生物 |
-
2015
- 2015-02-17 GE GEAP201814248A patent/GEAP201814248A/en unknown
- 2015-02-17 EA EA201691447A patent/EA031132B1/ru not_active IP Right Cessation
- 2015-02-17 MX MX2016010777A patent/MX2016010777A/es unknown
- 2015-02-17 US US15/119,639 patent/US20170066741A1/en not_active Abandoned
- 2015-02-17 CN CN201580009034.XA patent/CN106029639B/zh not_active Expired - Fee Related
- 2015-02-17 JP JP2016551851A patent/JP6483146B2/ja not_active Expired - Fee Related
- 2015-02-17 GE GEAP201514248A patent/GEP20186892B/en unknown
- 2015-02-17 SG SG11201606812WA patent/SG11201606812WA/en unknown
- 2015-02-17 WO PCT/EP2015/053327 patent/WO2015124576A1/en not_active Ceased
- 2015-02-17 RU RU2016133626A patent/RU2016133626A/ru not_active Application Discontinuation
- 2015-02-17 AU AU2015220873A patent/AU2015220873A1/en not_active Abandoned
- 2015-02-17 MA MA39225A patent/MA39225A1/fr unknown
- 2015-02-17 TW TW104105281A patent/TW201609700A/zh unknown
- 2015-02-17 CR CR20160352A patent/CR20160352A/es unknown
- 2015-02-17 UA UAA201608414A patent/UA117695C2/uk unknown
- 2015-02-17 CA CA2940028A patent/CA2940028A1/en not_active Abandoned
- 2015-02-17 EP EP15707304.0A patent/EP3107897A1/en not_active Withdrawn
- 2015-02-17 AP AP2016009370A patent/AP2016009370A0/en unknown
- 2015-02-17 PE PE2016001299A patent/PE20161225A1/es not_active Application Discontinuation
- 2015-02-17 KR KR1020167021930A patent/KR20160115936A/ko not_active Withdrawn
- 2015-02-18 AR ARP150100475A patent/AR099489A1/es unknown
- 2015-02-19 US US14/625,658 patent/US9353084B2/en not_active Expired - Fee Related
-
2016
- 2016-07-21 IL IL246875A patent/IL246875A0/en unknown
- 2016-07-28 DO DO2016000194A patent/DOP2016000194A/es unknown
- 2016-08-11 PH PH12016501600A patent/PH12016501600A1/en unknown
- 2016-08-17 CL CL2016002072A patent/CL2016002072A1/es unknown
- 2016-09-09 EC ECIEPI201672941A patent/ECSP16072941A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AR099489A1 (es) | 2016-07-27 |
| US9353084B2 (en) | 2016-05-31 |
| TW201609700A (zh) | 2016-03-16 |
| MA39225A1 (fr) | 2017-04-28 |
| GEAP201814248A (en) | 2018-04-10 |
| WO2015124576A1 (en) | 2015-08-27 |
| CN106029639B (zh) | 2019-01-08 |
| AU2015220873A1 (en) | 2016-08-11 |
| CA2940028A1 (en) | 2015-08-27 |
| GEP20186892B (en) | 2018-09-10 |
| AP2016009370A0 (en) | 2016-08-31 |
| UA117695C2 (uk) | 2018-09-10 |
| CN106029639A (zh) | 2016-10-12 |
| IL246875A0 (en) | 2016-08-31 |
| CR20160352A (es) | 2016-10-20 |
| ECSP16072941A (es) | 2017-02-24 |
| EA201691447A1 (ru) | 2016-12-30 |
| US20150232449A1 (en) | 2015-08-20 |
| US20170066741A1 (en) | 2017-03-09 |
| RU2016133626A (ru) | 2018-03-20 |
| DOP2016000194A (es) | 2016-09-30 |
| RU2016133626A3 (esLanguage) | 2018-09-25 |
| PH12016501600A1 (en) | 2017-02-06 |
| SG11201606812WA (en) | 2016-09-29 |
| PE20161225A1 (es) | 2016-12-04 |
| KR20160115936A (ko) | 2016-10-06 |
| MX2016010777A (es) | 2016-10-26 |
| JP2017506237A (ja) | 2017-03-02 |
| EP3107897A1 (en) | 2016-12-28 |
| JP6483146B2 (ja) | 2019-03-13 |
| EA031132B1 (ru) | 2018-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2016002072A1 (es) | 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer | |
| PL3717471T3 (pl) | Nowe związki i zawierające je kompozycje farmaceutyczne do leczenia chorób | |
| EA201692301A1 (ru) | Производные бороновой кислоты и их терапевтическое применение | |
| CL2016001895A1 (es) | Compuestos | |
| IL255509B (en) | Compounds as modulators of ccr2, pharmaceutical preparations containing them and their use in the treatment of diseases | |
| EA201691582A1 (ru) | Новые фармацевтические препараты | |
| CL2016002027A1 (es) | Ciclopropilamina como inhibidor de la lsd1 | |
| EA201691988A1 (ru) | Производные бороновой кислоты и их терапевтическое применение | |
| CR20160456A (es) | Compuestos de heteroarilo o arilo bibíclicos fusionados | |
| EA201790273A1 (ru) | Флагеллиновые композиции и их применение | |
| MX382033B (es) | Compuestos heterocíclicos para utilizarlos en el tratamiento de trastornos mediados por pi3k-gamma. | |
| JO3512B1 (ar) | مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز | |
| EP3263132C0 (en) | COMPOSITION FOR THE TREATMENT OF DISEASES ASSOCIATED WITH IL-6 | |
| MX385332B (es) | Moduladores de ror-gamma. | |
| MX2016012574A (es) | Compuestos heteroarilo sustituidos y metodos de uso. | |
| CL2016002091A1 (es) | Compuesto de triazina y su uso para fines medicinales | |
| CO2017007121A2 (es) | Compuestos bicíclicos fusionados para el tratamiento de enfermedades | |
| CL2016001918A1 (es) | Heteroaril amidas como inhibidores de agregación de proteína | |
| CL2015002897A1 (es) | Inhibidores de bace1 | |
| CL2016003074A1 (es) | Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer. | |
| EA201791259A1 (ru) | Производные пиперидина в качестве ингибиторов hdac1/2 | |
| UY34615A (es) | Nuevos compuestos útiles para el tratamiento de enfermedades degenerativas e inflamatorias. | |
| MX2019001634A (es) | Compuestos amidas, composiciones farmacéuticas de estos y métodos para utilizarlos. | |
| DOP2016000297A (es) | Composiciones farmacéuticas útiles para tratar enfermedades infecciosas | |
| EP3185862A4 (en) | PROTECTIVE METALLOTHIONEIN ANALOGUES, THEIR COMPOSITIONS AND THEIR USE IN THE TREATMENT OF PATHOGENIC DISEASES |